Role of Thalidomide in prevention of stroke due to basal exudates in Tuberculous Meningitis

Thalidomide as treatment of basal exudates in Tuberculous Meningitis: A prospective randomized open blinded endpoint (PROBE) study. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/078846

Enrollment

Registered

2025-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A170- Tuberculous meningitis

Interventions

Intervention1: Thalidomide: The patients will be given oral Thalidomide as per 2-4 mg/kg body weight and the target dose will be based on the tolerability of the patient. The treatment will be given f

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age greater than 12 years 2. Patient of Tuberculous meningitis 3. Basal exudates

Exclusion criteria

Exclusion criteria: (1) Patients who have taken ATT for more than 8 weeks. (2) Patients who have contraindication to MRI brain. (3) HIV positive. (4) Patients with hepatic or renal dysfunction, malignancy, pregnancy and lactation. (5) Patients who are diagnosed as multi drug resistant tuberculosis (MDR-TB) (6) Patients who refuse to consent for the study.

Design outcomes

Primary

Measure	Time frame
The primary outcome will be occurrence of stroke on MRI (New MRI proven brain infarction) at 3 month with or without clinical evidence of focal deficit.Timepoint: 3 months	—

Secondary

Measure	Time frame
The secondary outcome will be death and functional outcome at 3 monthsTimepoint: 3 months	—

Countries

India

Contacts

Public ContactRajesh Kumar Singh

AIIMS

drrajeshrims679@gmail.com01126594049

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026